588 related articles for article (PubMed ID: 23249108)
1. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
3. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
5. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
9. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
14. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
15. Vemurafenib: the first drug approved for BRAF-mutant cancer.
Bollag G; Tsai J; Zhang J; Zhang C; Ibrahim P; Nolop K; Hirth P
Nat Rev Drug Discov; 2012 Nov; 11(11):873-86. PubMed ID: 23060265
[TBL] [Abstract][Full Text] [Related]
16. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
17. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Jang S; Atkins MB
Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib for the treatment of melanoma.
Jordan EJ; Kelly CM
Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
[TBL] [Abstract][Full Text] [Related]
20. New targeted therapies in melanoma.
Kudchadkar RR; Gonzalez R; Lewis K
Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
